Literature DB >> 19039590

Prognostic factors in T3b renal cell carcinoma.

Benjamin J Coons1, Andrew A Stec, Kelly L Stratton, Sam S Chang, Michael S Cookson, S Duke Herrell, Joseph A Smith, Peter E Clark.   

Abstract

OBJECTIVES: We reviewed our patients with pathologic T3b renal cell carcinoma (RCC) to determine which factors influenced survival in this high risk patient group.
METHODS: From April 1988 to August 2006, 722 patients underwent nephrectomy for RCC at Vanderbilt University. 128 patients (17%) had T3b disease by 2002 AJCC TNM staging criteria. 31 (24%) of these patients had known metastases at the time of nephrectomy. Patient demographics, clinical, and pathological characteristics were collected.
RESULTS: There were 95 men (74%) and 33 women (26%) whose median age was 64 years (range 35-87). Median follow-up was 25.2 months (0-124). Median follow-up among those still alive at last follow up was 45.8 months (2.4-114). For overall survival (OS), disease specific survival (DSS), and recurrence free survival (RFS), non-clear cell histology, grade, presence of sarcomatoid features, LN positive disease, presence of necrosis, positive margins, and metastasis present at the time of nephrectomy were all associated with worse outcomes. Race, gender, ASA class, age, and inferior vena cava (IVC) involvement were not associated with outcome. On multivariate analysis, metastasis at the time of nephrectomy, margin involvement, and the presence of necrosis were independently associated with decreased OS and DSS. The presence of necrosis and lymph node involvement were independent predictors of worse RFS.
CONCLUSIONS: Our data suggests that in patients with T3b RCC, the presence or absence of macroscopic necrosis should be included as part of the pathology report to help guide prognosis in this high risk patient group.

Entities:  

Mesh:

Year:  2008        PMID: 19039590      PMCID: PMC2963091          DOI: 10.1007/s00345-008-0358-9

Source DB:  PubMed          Journal:  World J Urol        ISSN: 0724-4983            Impact factor:   4.226


  13 in total

1.  Cancer specific survival for patients with pT3 renal cell carcinoma-can the 2002 primary tumor classification be improved?

Authors:  Bradley C Leibovich; John C Cheville; Christine M Lohse; Horst Zincke; Eugene D Kwon; Igor Frank; R Houston Thompson; Michael L Blute
Journal:  J Urol       Date:  2005-03       Impact factor: 7.450

2.  Prognostic factors of renal cell carcinoma with extension into inferior vena cava.

Authors:  Masahiro Tanaka; Kiyohide Fujimoto; Eijiro Okajima; Nobumichi Tanaka; Katsunori Yoshida; Yoshihiko Hirao
Journal:  Int J Urol       Date:  2008-05       Impact factor: 3.369

3.  Long-term results of resection of renal cell cancer with extension into inferior vena cava.

Authors:  J A Libertino; L Zinman; E Watkins
Journal:  J Urol       Date:  1987-01       Impact factor: 7.450

4.  Renal cell carcinoma with tumor thrombus extension: biology, role of nephrectomy and response to immunotherapy.

Authors:  Amnon Zisman; Jeff A Wieder; Allan J Pantuck; Debby H Chao; Frederick Dorey; Jonathan W Said; Barbara J Gitlitz; Jean B deKernion; Robert A Figlin; Arie S Belldegrun
Journal:  J Urol       Date:  2003-03       Impact factor: 7.450

5.  Resection of metastatic renal cell carcinoma.

Authors:  J P Kavolius; D P Mastorakos; C Pavlovich; P Russo; M E Burt; M S Brady
Journal:  J Clin Oncol       Date:  1998-06       Impact factor: 44.544

6.  Cancer statistics, 2008.

Authors:  Ahmedin Jemal; Rebecca Siegel; Elizabeth Ward; Yongping Hao; Jiaquan Xu; Taylor Murray; Michael J Thun
Journal:  CA Cancer J Clin       Date:  2008-02-20       Impact factor: 508.702

7.  Surgical management and prognosis of renal cell carcinoma invading the vena cava.

Authors:  P A Hatcher; E E Anderson; D F Paulson; C C Carson; J E Robertson
Journal:  J Urol       Date:  1991-01       Impact factor: 7.450

8.  Prognostic factors for renal cell carcinoma with tumor thrombus extension.

Authors:  Tobias Klatte; Allan J Pantuck; Stephen B Riggs; Mark D Kleid; Brian Shuch; Nazy Zomorodian; Fairooz F Kabbinavar; Arie S Belldegrun
Journal:  J Urol       Date:  2007-08-14       Impact factor: 7.450

9.  The Mayo Clinic experience with surgical management, complications and outcome for patients with renal cell carcinoma and venous tumour thrombus.

Authors:  Michael L Blute; Bradley C Leibovich; Christine M Lohse; John C Cheville; Horst Zincke
Journal:  BJU Int       Date:  2004-07       Impact factor: 5.588

10.  Evaluation of tumor thrombi in the inferior vena cava with intraoperative ultrasound.

Authors:  Carlo Trombetta; Giovanni Liguori; Stefano Bucci; Sara Benvenuto; Giulio Garaffa; Emanuele Belgrano
Journal:  World J Urol       Date:  2007-07-03       Impact factor: 4.226

View more
  4 in total

1.  Renal cell carcinoma and tumour thrombus in the inferior vena cava: clinical outcome of 98 consecutive patients and the prognostic value of preoperative parameters.

Authors:  Christian Niedworok; Bettina Dörrenhaus; Frank Vom Dorp; Jarowit Adam Piotrowski; Stephan Tschirdewahn; Tibor Szarvas; Herbert Rübben; Marcus Schenck
Journal:  World J Urol       Date:  2014-11-30       Impact factor: 4.226

2.  Urinary collecting system invasion reflects adverse long-term outcome and is associated with simultaneous metastatic spread at the time of surgery and with multilocular dissemination during postsurgical follow-up in renal cell cancer.

Authors:  Sabine Brookman-Amissah; Matthias May; Knut Albrecht; Thomas Herrmann; Jan Roigas; Christian Peter Gilfrich; Sandra Pflanz; Sven Gunia
Journal:  World J Urol       Date:  2009-05-29       Impact factor: 4.226

3.  The prognostic value and clinicopathological features of sarcomatoid differentiation in patients with renal cell carcinoma: a systematic review and meta-analysis.

Authors:  Zhenlei Zha; Hu Zhao; Yejun Feng; Lijin Zhang; Bin Wu
Journal:  Cancer Manag Res       Date:  2018-06-22       Impact factor: 3.989

Review 4.  Tumor necrosis as a prognostic variable for the clinical outcome in patients with renal cell carcinoma: a systematic review and meta-analysis.

Authors:  Lijin Zhang; Zhenlei Zha; Wei Qu; Hu Zhao; Jun Yuan; Yejun Feng; Bin Wu
Journal:  BMC Cancer       Date:  2018-09-03       Impact factor: 4.430

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.